In recent years, China has intensified its anti-corruption efforts in the healthcare sector, exposing numerous cases involving ‘medical parasites’—individuals who exploit their positions for personal gain. These corrupt actors often include hospital administrators or medical staff who accept kickbacks, issue falsified invoices, or manipulate bidding processes in areas such as pharmaceutical procurement, medical equipment purchases, and infrastructure projects. For instance, some hospital directors have been found to receive millions of yuan in kickbacks by designating specific suppliers, while others colluded with pharmaceutical companies to overprescribe medications or inflate treatment items to fraudulently claim public health insurance funds. Such misconduct not only inflates healthcare costs but also severely undermines patient welfare and equitable access to public medical resources. Since 2023, the National Health Commission, in collaboration with multiple agencies, has launched a targeted crackdown, resulting in the investigation of hundreds of individuals, including employees of multinational pharmaceutical firms. Experts emphasize that eradicating corruption requires systemic reforms—such as transparent procurement systems, strengthened internal audits, integrity records for medical personnel, and improved whistleblower incentives. Only by establishing a long-term mechanism that ensures officials ‘dare not, cannot, and do not want to’ engage in corruption can the healthcare ecosystem be truly cleansed and public health rights safeguarded.
近年来，中国医疗行业反腐力度持续加大，多起涉及‘医疗蛀虫’的腐败案件被曝光。这些‘蛀虫’通常指利用职务之便，在药品采购、设备引进、基建工程等环节中收受回扣、虚开发票、操纵招标的医院管理人员或医务人员。例如，有院长通过指定供应商获取高额回扣，单笔金额高达数百万元；还有医生与药企勾结，通过过度开药、虚增诊疗项目等方式套取医保基金。此类行为不仅推高了医疗成本，还严重损害患者利益和公共医疗资源公平分配。2023年以来，国家卫健委联合多部门开展专项整治行动，已查处数百名涉案人员，部分案件甚至牵涉跨国医药企业。专家指出，根治医疗腐败需从制度层面入手，包括推进阳光采购、强化内部审计、建立医务人员廉洁档案以及完善举报奖励机制。唯有构建‘不敢腐、不能腐、不想腐’的长效机制，才能真正净化医疗生态，保障人民群众健康权益。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/19728.html